Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ARA NYSE:GRDN NASDAQ:NVAX NASDAQ:WVE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARAAmerican Renal Associates$11.52$11.50$5.57▼$11.98$397.94M1.11106,940 shs9,831 shsGRDNGuardian Pharmacy Services$25.83-1.7%$21.28$14.16▼$26.91$1.66BN/A206,149 shs417,788 shsNVAXNovavax$7.84+2.8%$7.30$5.01▼$15.22$1.24B2.58.43 million shs8.46 million shsWVEWAVE Life Sciences$10.15+4.0%$7.93$5.04▼$16.74$1.55B-0.951.65 million shs2.25 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARAAmerican Renal Associates0.00%0.00%0.00%0.00%0.00%GRDNGuardian Pharmacy Services-1.55%+9.45%+25.06%+16.61%+2,582,999,900.00%NVAXNovavax+2.75%-18.16%0.00%+8.14%-39.41%WVEWAVE Life Sciences+4.00%+4.00%+18.57%+70.59%+73.50%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARAAmerican Renal AssociatesN/AN/AN/AN/AN/AN/AN/AN/AGRDNGuardian Pharmacy Services0.8844 of 5 stars1.50.00.00.03.22.50.0NVAXNovavax4.6338 of 5 stars3.12.00.04.73.00.83.1WVEWAVE Life Sciences4.8047 of 5 stars4.51.00.04.83.54.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARAAmerican Renal Associates 0.00N/AN/AN/AGRDNGuardian Pharmacy Services 3.00Buy$25.67-0.63% DownsideNVAXNovavax 2.13Hold$15.5798.62% UpsideWVEWAVE Life Sciences 2.93Moderate Buy$20.2799.67% UpsideCurrent Analyst Ratings BreakdownLatest ARA, NVAX, GRDN, and WVE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/20/2025NVAXNovavaxBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Underperform$9.00 ➝ $7.008/4/2025WVEWAVE Life SciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$19.007/31/2025WVEWAVE Life SciencesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$24.00 ➝ $21.007/28/2025WVEWAVE Life SciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$24.007/22/2025NVAXNovavaxBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$10.00 ➝ $9.007/16/2025WVEWAVE Life SciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$16.006/23/2025WVEWAVE Life SciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$18.006/17/2025NVAXNovavaxCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSell$6.006/11/2025WVEWAVE Life SciencesRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$14.00(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARAAmerican Renal Associates$822.52M0.48$1.69 per share6.80$2.59 per share4.45GRDNGuardian Pharmacy Services$1.23B1.33$0.25 per share105.40$2.84 per share9.10NVAXNovavax$682.16M1.87N/AN/A$0.23 per share34.09WVEWAVE Life Sciences$108.30M14.91N/AN/A$0.88 per share11.53Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARAAmerican Renal Associates-$13.79M$0.26N/AN/AN/A-2.04%-3.56%-0.24%N/AGRDNGuardian Pharmacy Services-$87.29M-$1.52N/A30.75N/A-6.90%-52.41%-24.17%11/11/2025 (Estimated)NVAXNovavax-$187.50M$2.283.4498.000.1039.20%-142.33%28.65%11/11/2025 (Estimated)WVEWAVE Life Sciences-$97.01M-$0.90N/AN/AN/AN/A-78.45%-41.51%11/11/2025 (Estimated)Latest ARA, NVAX, GRDN, and WVE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025NVAXNovavax-$0.07$0.62+$0.69$0.62$149.19 million$239.24 million7/30/2025Q2 2025WVEWAVE Life Sciences-$0.29-$0.31-$0.02-$0.31$11.52 million$8.70 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARAAmerican Renal AssociatesN/AN/AN/AN/AN/AGRDNGuardian Pharmacy ServicesN/AN/AN/AN/AN/ANVAXNovavaxN/AN/AN/AN/AN/AWVEWAVE Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARAAmerican Renal Associates7.541.051.02GRDNGuardian Pharmacy ServicesN/A1.180.88NVAXNovavax5.932.362.34WVEWAVE Life SciencesN/A2.562.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARAAmerican Renal Associates78.42%GRDNGuardian Pharmacy ServicesN/ANVAXNovavax53.04%WVEWAVE Life Sciences89.73%Insider OwnershipCompanyInsider OwnershipARAAmerican Renal Associates9.50%GRDNGuardian Pharmacy Services63.71%NVAXNovavax1.00%WVEWAVE Life Sciences23.98%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARAAmerican Renal Associates4,97734.54 millionN/AOptionableGRDNGuardian Pharmacy Services3,40063.32 million22.97 millionN/ANVAXNovavax1,990162.42 million160.80 millionOptionableWVEWAVE Life Sciences240159.14 million120.98 millionOptionableARA, NVAX, GRDN, and WVE HeadlinesRecent News About These CompaniesConnor Clark & Lunn Investment Management Ltd. Has $1.02 Million Stock Position in WAVE Life Sciences Ltd. $WVEAugust 19, 2025 | marketbeat.com29,572 Shares in WAVE Life Sciences Ltd. (NASDAQ:WVE) Bought by Wealthedge Investment Advisors LLCAugust 18, 2025 | marketbeat.comWAVE Life Sciences (NASDAQ:WVE) Trading Up 7.8% - Still a Buy?August 17, 2025 | marketbeat.comWAVE Life Sciences Ltd. (NASDAQ:WVE) Director Sells $85,192.70 in StockAugust 15, 2025 | marketbeat.comWave Life Sciences moved to not rated at JPMorganAugust 15, 2025 | msn.comInsider Selling: WAVE Life Sciences Ltd. (NASDAQ:WVE) Director Sells 9,670 Shares of StockAugust 14, 2025 | insidertrades.comWave Life Sciences Shareholders Approve Key ProposalsAugust 11, 2025 | msn.comWave Life Sciences Earnings Call: Clinical Advances Amid Financial ChallengesAugust 9, 2025 | theglobeandmail.comKen Takanashi Sells 4,872 Shares of WAVE Life Sciences Ltd. (NASDAQ:WVE) StockAugust 8, 2025 | marketbeat.comWAVE Life Sciences Ltd. (NASDAQ:WVE) Director Ken Takanashi Sells 4,872 SharesAugust 8, 2025 | insidertrades.comWAVE Life Sciences (NASDAQ:WVE) Now Covered by Canaccord Genuity GroupAugust 5, 2025 | marketbeat.comWAVE Life Sciences Ltd. (NASDAQ:WVE) Holdings Trimmed by TD Asset Management IncAugust 5, 2025 | marketbeat.comCanaccord Genuity Initiates Coverage of Wave Life Sciences (WVE) with Buy RecommendationAugust 5, 2025 | msn.comWave Life Sciences is a new Buy at Canaccord Genuity on near-term catalystsAugust 5, 2025 | msn.comB. Riley Reduces Earnings Estimates for WAVE Life SciencesAugust 4, 2025 | marketbeat.comFY2025 Earnings Forecast for WVE Issued By Cantor FitzgeraldAugust 4, 2025 | marketbeat.comResearch Analysts Issue Forecasts for WVE FY2025 EarningsAugust 4, 2025 | marketbeat.comQ3 EPS Forecast for WAVE Life Sciences Reduced by AnalystAugust 4, 2025 | marketbeat.comQ3 EPS Estimates for WAVE Life Sciences Decreased by WedbushAugust 4, 2025 | marketbeat.comWAVE Life Sciences (NASDAQ:WVE) Trading 6.3% Higher - Here's WhyAugust 2, 2025 | marketbeat.comWAVE Life Sciences (NASDAQ:WVE) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPSAugust 2, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 2025Why the American Eagle Stock Rally Isn't Just Speculation By Gabriel Osorio-Mazilli | July 28, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 20253 Stocks Riding the AI Data Center Buildout WaveBy Chris Markoch | August 6, 2025IPO Market Stays Hot With These 2 Debuting StocksBy Dan Schmidt | August 11, 2025ARA, NVAX, GRDN, and WVE Company DescriptionsAmerican Renal Associates NYSE:ARAAmerican Renal Associates Holdings, Inc. operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease. As of December 31, 2019, it operated 246 dialysis clinics in partnership with 400 nephrologist partners treating approximately 17,300 patients in 27 states and the District of Columbia. The company was founded in 1999 and is headquartered in Beverly, Massachusetts.Guardian Pharmacy Services NYSE:GRDN$25.83 -0.46 (-1.75%) Closing price 08/22/2025 03:59 PM EasternExtended Trading$25.80 -0.03 (-0.14%) As of 08/22/2025 05:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company's Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs. The company was founded in 2003 and is based in Atlanta, Georgia.Novavax NASDAQ:NVAX$7.84 +0.21 (+2.75%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$7.88 +0.04 (+0.57%) As of 08/22/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.WAVE Life Sciences NASDAQ:WVE$10.15 +0.39 (+4.00%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$10.22 +0.07 (+0.69%) As of 08/22/2025 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet’s Breakout Potential: From Laggard to AI Leader After Earnings Miss, Walmart Is Still a Top Consumer Staples Play Should You Join Buffett and Invest in Constellation Brands? Can Identity Security Fuel CrowdStrike’s Next Growth Phase? 3 Robotics Stocks at the Heart of the Robotics Revolution Analog Devices and an AI-Driven Semiconductor Supercycle Shopify’s Risk-Reward Profile Is Suddenly Red Hot 3 Reasons Salesforce Is a Bargain Right Now Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access